Profilové publikácie

PubMed Šereš M, Cholujová D, Bubenčíkova T, Breier A, Sulová Z. Tunicamycin depresses p-glycoprotein glycosylation without an effect on its membrane localization and drug efflux activity in l1210 cells. Int J Mol Sci. 12 (2011) 7772-7784. (IF2012=2.464)
PubMed Sulová Z, Mislovicová D, Gibalová L, Vajcnerová Z, Poláková E, Uhrík B, Tylková L, Kovarova A, Sedlák J, Breier A. Vincristine-induced overexpression of P-glycoprotein in L1210 cells is associated with remodeling of cell surface saccharides. J Proteome Res. 2009, 8, 513-20. (IF2012=5.056)
PubMed Sulová Z, Macejová D, Sereš M, Sedlák J, Brtko J, Breier A. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity. Toxicol in Vitro. 2008 22, 96-105 (IF2012=2.650)
PubMed Barancik M, Bohacova V, Sedlak J, Sulova Z, Breier A: LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glykoprotein-mediated multisrug resistance. Eur. J. Pharm. Sci. 29 (2006) 426-434 (IF2012=2.987)
PubMed Breier A, Barancik M, Sulova Z, Uhrik B. P-glycoprotein–implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets. 5, (2005), 457-68. (IF2012=4.000)
PubMed Fiala R, Sulova Z, El-Saggan AH, Uhrik B, Liptaj T, Dovinova I, Hanusovska E, Drobna Z, Barancik M, Breier A: P-glycoprotein-mediated multidrug resistance phenotype of L1210/VCR cells is associated with decreases of oligo- and/or polysaccharide contents. Biochim Biophys Acta. 1639, (2003), 213-224. (IF2012=4.910)
PubMed Barancik M, Bohacova V, Kvackajova J, Hudecova S, Krizanova O, Breier A: SB203580, a specific inhibitor of p38-MAPK pathway, is a new reversal agent of P-glycoprotein-mediated multidrug resistance. Eur. J. Pharm. Sci. 14, (2001), 29-36 (IF2012=2.987)